PLT Health Solutions has announced a company-wide strategic commitment that will shape its clinical research, ingredient development, and customer innovations around two connected tracks:

• Cellular longevity, the mechanistic, biomarker-driven solutions addressing cellular energy and the biology of aging
• Experiential benefits developed from translational research involving those cellular mechanisms

The first study that will be part of the Longevity Research Initiative is a six-month randomized clinical study on the company’s Kinexa Joint Longevity Complex, which will be presented by Jeremy Appleton, ND, at Vitafoods Europe on Wednesday, May 6 at 3:00 CEST in the New Ingredients Theater.

“There is an active discussion in the natural products industry about what ‘longevity’ really means, and how it differs from healthy aging or condition-specific solutions,” said Devin Stagg, president of PLT Health Solutions. “Our view is that longevity has to stay grounded in mechanistic science, but it also has to connect with tangible and meaningful outcomes that consumers can actually feel. It’s not just about extending lifespan, it’s about extending the ability to live those years well. Many current longevity solutions are future-focused investments that require a degree of belief in long-term outcomes. Experiential longevity lets consumers feel the benefits of impacting these key mechanisms in the near term while the foundational work continues to pay dividends over a lifetime.”

“The market for longevity has matured beyond early adopters and ‘biohackers,'” said Stagg. “There is a much larger consumer base looking to enhance their longevity and, in the process, enhance their everyday experience. By linking foundational mechanisms of aging to the performance of specific body systems, we can make longevity something people don’t just aspire to, but actively experience. The natural products business is evolving rapidly and it’s our goal to support our customers with innovations that address and enable this evolution.”

Kinexa Study: Focused on Structure and Comfort

The Kinexa study follows the initiative’s new research model by addressing a core mechanism of joint aging, the degradation of cartilage, meniscus, ligaments, synovium, and subchondral bone, while delivering experiential benefits to strength, mobility, and comfort. The results included improvements in knee strength, cartilage thickness, and health, significant improvements in ligament, meniscus, synovial, and subchondral bone health, as well as enhanced joint comfort and functionality.

The breadth and significance of the results, Appleton said, open new ways of thinking about joint health and mobility ingredients. “To date, most clinical work in the joint health sector has focused on enhancing comfort. But joints are load-bearing mechanical systems, and joint pain in aging typically reflects the structural changes occurring below the surface. Most ingredients on the market are likely impacting pain by reducing inflammation, but that is a short-term fix. Kinexa signals a new direction, because we have demonstrated improvements to the foundational structure of joints and these are the factors that contribute to joint health and mobility in the long-term. Comfort is how the joint feels today, structure is what determines whether it keeps working years from now. When cartilage, meniscus, ligaments, and the foundation beneath the cartilage stay strong and resilient, the joint can absorb shock, distribute load evenly, and remain stable through everyday life, training, aging, and wear-and-tear.”

Jennifer Murphy, head of innovation and clinical science, said that this model is a natural progression for the market. “The future of longevity innovation is not about adding years to life. It is about helping people stay active, capable, and resilient throughout those years. Kinexa shows how impacting cellular mechanisms can translate into benefits that matter in daily life. That is the essence of experiential longevity. From cellular health to body system performance to lived experience, these connections are inseparable. That gives brands a clearer, more compelling way to bring longevity to market and opens a broader framework for longevity innovation.”

Steve Fink, vice president of marketing, said that longevity research and product development is a way to help products that support healthy aging with a much broader demographic.

“Younger consumers are already buying longevity-relevant products and are looking for a new generation of solutions that will address mechanisms of longevity before they lead to decline. This group is in the best position to build lifelong supplement habits that the pursuit of longevity will require and capturing them will result in 30 years of loyalty. Our dual-track approach in the PLT Longevity Initiative is designed to help brands meet those consumers where they are and give them the innovation and scientific support they are looking for.”